Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Arena Pharmaceuticals, Inc. Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates February 23, 2022 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 17, 2022 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23 February 09, 2022 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 18, 2022 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 21, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A November 19, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 16, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Reports Third Quarter Financial Results and Key Program Updates November 04, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 21, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4 October 14, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 17, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences September 02, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 18, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Reports Second Quarter Financial Results and Key Program Updates August 05, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5 July 29, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases July 27, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 22, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development July 19, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 18, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Steven Schoch Elected to Arena Pharmaceuticals Board of Directors June 14, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE) June 09, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO) June 08, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments June 03, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 19, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments May 12, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5 April 28, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX April 23, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report April 19, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience April 19, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 16, 2021 From Arena Pharmaceuticals, Inc. Via Business Wire Tickers ARNA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.